TCT 2019: BD, VIVA Data Show Lower Paclitaxel Mortality Risk
BD said an independent Lutonix review found no significant link to deaths, while further meta-analysis from trade group VIVA showed a decline in the risk. Both studies were unveiled at the Transcatheter Cardiovascular Therapeutics (TCT) conference in San Francisco.
You may also be interested in...
An ongoing trial of Medtronic’s In.Pact Admiral paclitaxel-coated balloon found a four-year survival rate in line with what would be expected for the patient population and a relatively low rate of complications.
A meta-analysis that seemed to show an increased mortality risk tied to paclitaxel-coated balloons and stents sent shockwaves through the device industry last year. But a more complete data review funded by nonprofit group VIVA Physicians may show that the issue has been overestimated.